2 AI Healthcare Stocks to Buy Right Now

Core Insights - The impact of artificial intelligence (AI) on various sectors is significant, but many CEOs (56%) do not see substantial benefits from their AI investments [1] - The healthcare sector presents a unique opportunity for AI to improve outcomes and efficiency [2] Company Insights - Recursion Pharmaceuticals is leveraging AI to transform drug development, significantly reducing the time and cost associated with bringing new drugs to market [6] - The average cost to develop a drug is estimated between $900 million and $2 billion, with a high failure rate of 90% for drugs entering clinical trials [5] - Recursion's AI platform utilizes over 50 petabytes of data to help pharmaceutical companies identify promising drug candidates, thereby optimizing their R&D efforts [7] - The company is collaborating with established pharmaceutical firms like Sanofi and Roche to enhance drug development processes [8] - Recursion's revenue model is currently based on partnerships with drugmakers, with expectations for significant revenue growth in the upcoming fiscal year as developmental milestone payments increase [9] - The AI-powered drug development market is projected to grow at an average rate of 30% per year through 2035, indicating a robust future for companies like Recursion Pharmaceuticals [9]